Leukeran (chlorambucil) / GSK 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...6789101112131415161718»
  • ||||||||||  Review, Journal:  New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview. (Pubmed Central) -  Jun 9, 2020   
    In this regard, anti-TNF agents (infliximab and adalimumab) have shown the strongest results in terms of favorable outcomes. In this review, we discuss latest evidence concerning to the effectiveness of biologic therapy, and present new therapeutic approaches directed against immune components as potential novel therapies for NIU.
  • ||||||||||  Leukeran (chlorambucil) / GSK
    The regulation of FGFR signaling by RTK adaptor protein down-regulation through CROX (cluster regulation of RUNX) theory in DNPC (Virtual Meeting II: E-Posters) -  May 16, 2020 - Abstract #AACRII2020AACR-II_1778;    
    To achieve cluster regulations of RUNX(CROX), We screened our library and isolated our original Pan RUNX inhibitor based on gene switch technology ; Chlorambucil-conjugated Pyrrole Imidazole Polyamide (Chb-M’), which specifically binds to the common RUNX binding consensus sequence(TGTGGT) and inhibits RUNX target genes including the adaptor protein, consistently led to the deactivation of the FGFR signaling pathway and was effective against DNPC cell lines and was exceptionally well-tolerated in mice and exerted excellent efficacy against xenograft mice models of DNPC. Taken together, our work identified a novel interaction of RUNX family and the FGFR signaling pathway in DNPC, which can potentially be exploited in the management of this malignancy.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    [VIRTUAL] OUTCOMES IN DIFFUSE LARGE B-CELL LYMPHOMA IN THE VERY ELDERLY (>80 YEARS OLD) () -  May 16, 2020 - Abstract #EHA2020EHA_2108;    
    Treatment decisions are informed by patient fitness, co-morbidities, patient and family wishes, and impact patient outcome. Prospective trials are required in frail and elderly patients to better inform treatment decisions and optimal management strategies in DLBCL.
  • ||||||||||  cyclophosphamide intravenous / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    [VIRTUAL] SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS COMPARING THERAPIES FOR TREATMENT-NAÏVE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA () -  May 16, 2020 - Abstract #EHA2020EHA_1102;    
    Aims To assess the relative efficacy of VEN+G compared to G+Clb, Clb monotherapy; ibrutinib plus G (Ibr+G); ibrutinib plus rituximab (Ibr+R); ibrutinib monotherapy (Ibr); bendamustine plus rituximab (B+R); Clb+R; ofatumumab (O) plus Clb (O+Clb); and fludarabine, cyclophosphamide and R (FCR) in TN-CLL patients...In the scenario analysis, VEN+G showed benefit in PFS versus FCR. Future comparisons with more mature data across trials will provide more robust estimates of overall survival comparisons.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen
    [VIRTUAL] CHARACTERISTICS AND OUTCOME OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA AND PARTIAL RESPONSE TO VENETOCLAX-OBINUTUZUMAB () -  May 16, 2020 - Abstract #EHA2020EHA_1076;    
    Patients with uMRD in PB at EOT, N 67 Lymph nodes Total >15mm and 15mm and ≤ 20mm 21 > 20mm and < 72mm 16 BM Biopsy Not done 18 BM Biopsy Infiltration/Nodules 2 Splenomegaly (CT) 1 B Symptoms present 2 Hematology Parameters (Missing) 7 Conclusion This analysis shows that most frequent reason for patients being staged as PR after VenG were mild residual lymphadenopathy or missing bone marrow sample. The data indicate that patients who have PR after VenG have a similar outcome as patients with CR when uMRD levels are achieved.
  • ||||||||||  cyclophosphamide intravenous / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Contemporary real‐world treatment patterns of chronic lymphocytic leukaemia (CLL) in England () -  May 14, 2020 - Abstract #BSH2020BSH_442;    
    Fludarabine/cyclophosphamide/rituximab (FCR) and bendamustine/rituximab (BR) were the two most frequently used treatment modalities for CLL patients with a mean age at the start of treatment of 62 and 71 years respectively...Chlorambucil‐based combinations were found to be preferentially used in older patient groups with worse performance scores...Conclusion In this contemporary study of CLL patients with a first recorded systemic treatment, chemo‐immunotherapy (FCR / BR) continues to be the mainstay treatment modality of choice. The relative low usage of Ibrutinib in England likely reflects the restricted reimbursement conditions of this agent to patients with high‐risk cytogenomic features in the first‐line setting.
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD), Actemra IV (tocilizumab) / Roche, JW Pharma, cyclophosphamide intravenous / Generic mfg.
    Experiences of providing commercial Chimeric Antigen Receptor (CAR‐T) cell therapy at the Northern Centre for Cancer Care () -  May 14, 2020 - Abstract #BSH2020BSH_350;    
    Twelve patients received axicabtagene ciloleucel...All were conditioned with fludarabine and cyclophosphamide...Ten (67%) received tocilizumab...Four patients (29% of cohort available to follow‐up) have died after CAR‐T infusion. Progression‐free survival rates as calculated at standardised follow‐up points were 71% at 28 days, 31% at 3 months, and 27% at 6 months after CAR‐T infusion. One patient who had initial disease progression later had a subsequent complete response after receiving another line of treatment.
  • ||||||||||  cyclophosphamide intravenous / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo, Imbruvica (ibrutinib) / AbbVie, J&J
    Real‐world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the United Kingdom () -  May 14, 2020 - Abstract #BSH2020BSH_172;    
    Other therapies received included the combination of fludarabine, cyclophosphamide and rituximab (first‐line, 24·3%), bendamustine plus rituximab (first‐line, 20·9%; second‐line, 13·5%) and chlorambucil plus rituximab (first‐line, 8·5%). Overall, the median progression‐free survival was 28·7 months and median overall survival was not reached...Among patients who initiated further therapy following discontinuation of first‐ or second‐line ibrutinib (n = 13), venetoclax was the most common therapy (53·8%)...The majority of ibrutinib use was in the second‐line or later. AEs such as bruising and cytopenias were commonly reported in patients treated with ibrutinib.
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD), Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Real world outcomes for treatment of diffuse large B cell Lymphoma in patients aged 80 and over () -  May 14, 2020 - Abstract #BSH2020BSH_92;    
    The median OS of 33 months for patients treated with curative intent is similar to 29 months reported previously by the GELA group for R‐miniCHOP in patients aged over 80. However only 50% of this age group were felt to be fit enough to receive this treatment in our cohort and the survival for those treated palliatively was short indicating an unmet need for effective well‐tolerated treatment in this group.
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD), cyclophosphamide intravenous / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Treatment decisions in Waldenstrom's Macroglobulinaemia; outcomes from the South East Scotland Cancer Network () -  May 14, 2020 - Abstract #BSH2020BSH_36;    
    Rituximab, Cyclophosphamide, Dexamethasone (RCD) was the most common first‐line treatment (n = 18)...Alternative frontline regimens included R‐CVP (n = 4), R‐CHOP (n = 1) and R‐Bendamustine (n = 1)...Two patients had Bing‐Neel Syndrome and the third was frail and relapsed following first line Rituximab and Chlorambucil...Indeed, some unfit patients declined chemoimmunotherapy or were offered symptomatic management only. It is clear that many of these patients may have benefited from Ibrutinib and there will no doubt be an increase in Ibrutinib use going forward in this patient group.
  • ||||||||||  Indirect treatment comparison analysis of venetoclax + obinutuzumab with standard front‐line regimens for chronic lymphocytic leukaemia () -  May 14, 2020 - Abstract #BSH2020BSH_17;    
    However, there is an absence of head‐to‐head clinical evidence on the comparative efficacy of VenG versus standard 1L chemoimmunotherapy regimens like fludarabine + cyclophosphamide + rituximab (FCR) and bendamustine + R (BR)...Moreover, the PFS achieved with a 12‐month fixed duration VenG regimen appears similar to that achieved with a continuous ibrutinib‐based regimen. Although there are inherent limitations of ITCs, our study provides useful estimates of the relative efficacy of these regimens while we await the results of definitive, prospective, comparative trials such as GAIA/CLL13 (NCT0295005) and FLAIR (2013‐001944‐76).
  • ||||||||||  cyclophosphamide intravenous / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Clinical, Journal, Real-World Evidence:  First line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013. (Pubmed Central) -  May 9, 2020   
    Chlorambucil + prednisone was used in 39% (5% also received rituximab)...Overall response rate was 64%; chlorambucil 43%, fludarabine+cyclophosphamide+rituximab 84%, fludarabine+cyclophosphamide 75% and bendamustine + rituximab 75%...This is the largest retrospective, real-world cohort of consecutive first line treated chronic lymphocytic leukemia patients with a complete follow-up. In elderly patients, an unmet need for more effective, well-tolerated therapies was identified.
  • ||||||||||  Leukeran (chlorambucil) / GSK
    Journal, BRCA Biomarker, PARP Biomarker:  Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance. (Pubmed Central) -  Apr 26, 2020   
    Importantly, chlorambucil is substantially less toxic to normal cells and tissues in vitro and in vivo relative to cisplatin. Because chlorambucil and cisplatin are equally effective inhibitors of BRCA2-compromised tumours, our results indicate that chlorambucil has a higher therapeutic index than cisplatin in targeting BRCA-deficient tumours.
  • ||||||||||  Arimidex (anastrozole) / AstraZeneca, Remedica, Leukeran (chlorambucil) / GSK, Vocozo (voriconazole) / Orchid
    More Than Meets the Eye: Bronchopulmonary Leukemic Infiltrates in Chronic Lymphocytic Leukemia (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area A) -  Mar 15, 2020 - Abstract #ATS2020ATS_8919;    
    Hehas a history of chronic lymphocytic leukemia (CLL) complicated by hypogammaglobulinemia onintravenous immunoglobulin, localized melanoma status post excision, and left breast carcinoma statuspost mastectomy, radiation therapy, and adjuvant anastrazole...Aftersix weeks of treatment with voriconazole, his fevers persisted and CT of the chest demonstratedprogressive patchy ground-glass opacities and nodular consolidation...Time limited CLL specific therapy withobinutuzumab/chlorambucil was initiated.CLL accounts for 25-30% of all leukemias diagnosed in the United States...It is important to differentiate a possible “passenger effect”, which isa reactive, nonspecific recruitment of inflammatory cells into the lung parenchyma. An appropriatelevel of suspicion and a proper diagnosis can lead to discontinuation of antimicrobial therapy andinitiation of CLL directed therapy.
  • ||||||||||  paclitaxel / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Sick to My Stomach⋯and Lungs! A Rare Case of Pulmonary Maltoma (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area A) -  Mar 15, 2020 - Abstract #ATS2020ATS_8874;    
    Pulmonary non-Hodgkin’s lymphoma (NHL) is an infrequent entity with an annual incidence of 1:313000...Chemotherapy with rituximab-chlorambucil is considered first line...Blood. 2016;127(17):2082-92.
  • ||||||||||  Leukeran (chlorambucil) / GSK
    An Unusual Case of Asymptomatic Persistent Lung Infiltrates (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area A) -  Mar 15, 2020 - Abstract #ATS2020ATS_8813;    
    For symptomatic patient, chlorambucil-based chemotherapy is often the first choice...Despite stages of disease, MALT lymphoma has a good prognosis, with a 5-year and 10-year survival rate of 90% and 70% respectively. Follow-up visits every 3-6 months are recommended due to its high relapse rate.
  • ||||||||||  prednisolone / Generic mfg., fludarabine / Generic mfg., Leukeran (chlorambucil) / GSK
    Clinical, Retrospective data, Journal:  Presenting features and treatment outcomes of chronic lymphocytic leukaemia in a resource poor Southern Nigeria. (Pubmed Central) -  Mar 13, 2020   
    Majority of the patients presented in Binet stage C and were treated with chlorambucil-based drug combinations compared to more current treatment with Fludarabine-based combinations. A high serum alanine transaminase and alkaline phosphatase was found to positively correlate with survival amongst this patient population.
  • ||||||||||  Leukeran (chlorambucil) / GSK
    Journal, CINV:  Spray-Dried Silica Xerogel Nanoparticles as a Promising Gastroretentive Carrier System for the Management of Chemotherapy-Induced Nausea and Vomiting. (Pubmed Central) -  Feb 23, 2020   
    The current work aimed to develop spray-dried silica xerogel nanoparticles (SXNs) as a gastroretentive carrier for the dual delivery of chlorambucil (CHL) and granisetron hydrochloride (GR)...SXN4 system had the highest desirability (0.69); showing spherical nanoparticles (181.63 nm), negative zeta potential (-5.18 mV), promising EE% of 59.39% and 73.94% (for CHL and GR, respectively) and sustained CHL and GR release profiles characterized by low P (22.75% and 30.74%) and high P (60.36% and 99.33%), respectively. It had a mean pore diameter of 8.622 nm, a total porosity of 62.27%, a bulk density of 0.605 g/mL, a wetting time of 292 sec, zero lag time and a floating duration of at least 8 h. The prolongation in the mean residence time (MRT) and the promotion of the relative oral bioavailabilities of both drugs could unravel the potential of this system for the management of chemotherapy-induced nausea and vomiting.